Literature DB >> 14663478

The dark side of Ras: regulation of apoptosis.

Adrienne D Cox1, Channing J Der.   

Abstract

Mutational activation of Ras promotes oncogenesis by disrupting a multitude of normal cellular processes. Perhaps, best characterized and understood are the mechanisms by which oncogenic Ras promotes deregulated cell cycle progression and uncontrolled cellular proliferation. However, it is now clear that oncogenic Ras can also deregulate processes that control apoptosis. In light of the diversity of downstream effector targets known to facilitate Ras function, it is perhaps not surprising that Ras regulation of cell survival is complex, involving the balance and interplay of multiple signaling networks. While our understanding of these events is still far from complete, and is complicated by cell type and signaling context differences, several important mechanisms have begun to emerge. We review the role and mechanism of specific effectors in regulating the antiapoptotic (Raf, phosphatidylinositol 3-kinase and Tiam1) and apoptotic (Nore1 and RASSF1) actions of oncogenic Ras, and discuss the possibility that the effector actions of p120RasGAP make a significant contribution to Ras regulation of apoptotic events.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14663478     DOI: 10.1038/sj.onc.1207111

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  158 in total

1.  Mathematical modeling of K-Ras nanocluster formation on the plasma membrane.

Authors:  Tianhai Tian; Sarah J Plowman; Robert G Parton; Yoel Kloog; John F Hancock
Journal:  Biophys J       Date:  2010-07-21       Impact factor: 4.033

2.  Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.

Authors:  D Aydin; A Bilici; S Kayahan; D Yavuzer; M Basar; M Aliustaoglu
Journal:  Clin Transl Oncol       Date:  2015-10-12       Impact factor: 3.405

3.  RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated Dnmt1 degradation and promoting apoptosis.

Authors:  J Huang; A Stewart; B Maity; J Hagen; R L Fagan; J Yang; D E Quelle; C Brenner; R A Fisher
Journal:  Oncogene       Date:  2013-09-02       Impact factor: 9.867

4.  Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.

Authors:  Chaitali Parikh; Ramesh Subrahmanyam; Ruibao Ren
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

5.  RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis.

Authors:  M Lee Schmidt; Katharine R Hobbing; Howard Donninger; Geoffrey J Clark
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

6.  Improved binding of raf to Ras.GDP is correlated with biological activity.

Authors:  Christina Kiel; Daniel Filchtinski; Michael Spoerner; Gideon Schreiber; Hans Robert Kalbitzer; Christian Herrmann
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

7.  Oncogenic ras-induced down-regulation of autophagy mediator Beclin-1 is required for malignant transformation of intestinal epithelial cells.

Authors:  Byong Hoon Yoo; Xue Wu; Yongling Li; Mehnaaz Haniff; Takehiko Sasazuki; Senji Shirasawa; Eeva-Liisa Eskelinen; Kirill V Rosen
Journal:  J Biol Chem       Date:  2009-09-24       Impact factor: 5.157

8.  Active ras triggers death in glioblastoma cells through hyperstimulation of macropinocytosis.

Authors:  Jean H Overmeyer; Aparna Kaul; Erin E Johnson; William A Maltese
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

9.  The differential effects of wild-type and mutated K-Ras on MST2 signaling are determined by K-Ras activation kinetics.

Authors:  David Romano; Helene Maccario; Carolanne Doherty; Niall P Quinn; Walter Kolch; David Matallanas
Journal:  Mol Cell Biol       Date:  2013-03-04       Impact factor: 4.272

Review 10.  Heparanase and hepatocellular carcinoma: promoter or inhibitor?

Authors:  Shuo Dong; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.